dc.creator | Boziki M.K., Kesidou E., Theotokis P., Mentis A.-F.A., Karafoulidou E., Melnikov M., Sviridova A., Rogovski V., Boyko A., Grigoriadis N. | en |
dc.date.accessioned | 2023-01-31T07:40:22Z | |
dc.date.available | 2023-01-31T07:40:22Z | |
dc.date.issued | 2020 | |
dc.identifier | 10.3390/brainsci10040234 | |
dc.identifier.issn | 20763425 | |
dc.identifier.uri | http://hdl.handle.net/11615/72073 | |
dc.description.abstract | An increase of multiple sclerosis (MS) incidence has been reported during the last decade, and this may be connected to environmental factors. This review article aims to encapsulate the current advances targeting the study of the gut–brain axis, which mediates the communication between the central nervous system and the gut microbiome. Clinical data arising from many research studies, which have assessed the effects of administered disease-modifying treatments in MS patients to the gut microbiome, are also recapitulated. © 2020 by the authors. Licensee MDPI, Basel, Switzerland. | en |
dc.language.iso | en | en |
dc.source | Brain Sciences | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85084051878&doi=10.3390%2fbrainsci10040234&partnerID=40&md5=adbd734d17ece9cede5d462226a54d3d | |
dc.subject | alemtuzumab | en |
dc.subject | brain derived neurotrophic factor | en |
dc.subject | fingolimod | en |
dc.subject | fumaric acid dimethyl ester | en |
dc.subject | gamma interferon | en |
dc.subject | glatiramer | en |
dc.subject | granzyme B | en |
dc.subject | HLA DRB1 antigen | en |
dc.subject | interleukin 10 | en |
dc.subject | interleukin 13 | en |
dc.subject | interleukin 17 | en |
dc.subject | interleukin 2 | en |
dc.subject | interleukin 27 | en |
dc.subject | interleukin 4 | en |
dc.subject | interleukin 6 | en |
dc.subject | leptin | en |
dc.subject | myelin oligodendrocyte glycoprotein | en |
dc.subject | myeloid differentiation factor 88 | en |
dc.subject | natalizumab | en |
dc.subject | retinoic acid | en |
dc.subject | STAT5 protein | en |
dc.subject | syndecan 1 | en |
dc.subject | teriflunomide | en |
dc.subject | transforming growth factor beta | en |
dc.subject | transforming growth factor beta1 | en |
dc.subject | tumor necrosis factor | en |
dc.subject | vitamin D | en |
dc.subject | Actinobacteria | en |
dc.subject | autoimmunity | en |
dc.subject | Bacteroides fragilis | en |
dc.subject | blood brain barrier | en |
dc.subject | chronic lymphatic leukemia | en |
dc.subject | Clostridiales | en |
dc.subject | cytokine production | en |
dc.subject | dendritic cell | en |
dc.subject | diet supplementation | en |
dc.subject | environmental factor | en |
dc.subject | Expanded Disability Status Scale | en |
dc.subject | Faecalibacterium | en |
dc.subject | fecal microbiota transplantation | en |
dc.subject | Firmicutes | en |
dc.subject | human | en |
dc.subject | immune response | en |
dc.subject | immunological tolerance | en |
dc.subject | innate immunity | en |
dc.subject | intestine flora | en |
dc.subject | Lactobacillales | en |
dc.subject | Lactobacillus rhamnosus | en |
dc.subject | microbial diversity | en |
dc.subject | microbial metabolism | en |
dc.subject | microbiome | en |
dc.subject | multiple sclerosis | en |
dc.subject | nerve cell plasticity | en |
dc.subject | nervous system development | en |
dc.subject | nonhuman | en |
dc.subject | Proteobacteria | en |
dc.subject | regulatory T lymphocyte | en |
dc.subject | Review | en |
dc.subject | T lymphocyte | en |
dc.subject | tumor associated leukocyte | en |
dc.subject | MDPI AG | en |
dc.title | Microbiome in multiple sclerosis; where are we, what we know and do not know | en |
dc.type | other | en |